Imunon, Inc. is a clinical stage oncology drug company. The company is headquartered in Lawrenceville, New Jersey and currently employs 25 full-time employees. The firm is focused on advancing a portfolio of treatments that harness the body’s natural mechanisms across an array of human diseases, constituting a differentiating approach from conventional therapies. The firm is developing its non-viral DNA technology across its modalities. The first modality, TheraPlas, is developed for the gene-based delivery of cytokines and other therapeutic proteins in the treatment of solid tumors. The second modality, PlaCCine, is developed for the gene delivery of viral antigens that can elicit a strong immunological response. The Company’s lead clinical program, IMNN-001, is a DNA-based immunotherapy for the localized treatment of advanced ovarian cancer that has completed Phase 2 development. IMNN-001 works by instructing the body to produce safe and durable levels of powerful cancer-fighting molecules, such as interleukin-12 and interferon gamma, at the tumor site.
Follow-Up Questions
Qui est le CEO de Imunon Inc ?
Dr. Stacy Lindborg est le President de Imunon Inc, il a rejoint l'entreprise depuis 2021.
Quelle est la performance du prix de l'action IMNN ?
Le prix actuel de IMNN est de $5.07, il a decreased de 0% lors de la dernière journée de trading.
Quels sont les thèmes d'affaires principaux ou les industries de Imunon Inc ?
Imunon Inc appartient à l'industrie Biotechnology et le secteur est Health Care
Quelle est la capitalisation boursière de Imunon Inc ?
La capitalisation boursière actuelle de Imunon Inc est de $12.7M
Est-ce que Imunon Inc est un achat, une vente ou un maintien ?
Selon les analystes de Wall Street, 5 analystes ont établi des notations d'analystes pour Imunon Inc, y compris 2 achat fort, 6 achat, 2 maintien, 0 vente et 2 vente forte
